PDS Biotechnology Corp (FRA:EU6)
€ 3.082 -0.152 (-4.7%) Market Cap: 105.72 Mil Enterprise Value: 66.43 Mil PE Ratio: 0 PB Ratio: 3.33 GF Score: 33/100

PDS Biotechnology Corp Oncology R&D Day Transcript

Jun 16, 2021 / 12:00PM GMT
Release Date Price: €8.1 (+1.25%)
Operator

Hello, and welcome to the PDS Biotechnology R&D Day. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Deanne Randolph, Vice President, Commercial Development. Please go ahead.

Deanne Randolph
PDS Biotechnology Corporation - VP of Commercial Development & Head of IR

Good morning, and welcome to PDS Biotechnology's Oncology R&D Day Teleconference and Webcast. With me today are Dr. Frank Bedu-Addo, Chief Executive Officer; Dr. Lauren V. Wood, Chief Medical Officer; and Dr. Jeffrey Schlom; Dr. Caroline Jochems; and Dr. Julius Strauss from the National Cancer Institute. I will provide formal introductions in a moment.

But before we begin, I would like to caution listeners that comments made by management during the conference call will include forward-looking statements within the meaning of Federal Securities laws, including the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve material risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot